FDA Oncology Announcements

Thoracic × Clear all

125 Announcements

FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer

Drug: Hernexeos (zongertinib) · ERBB2 inhibitor
Condition: Thoracic

FDA approves amivantamab and hyaluronidase-lpuj for subcutaneous injection

Trial: PALOMA-3
Drug: Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) · Anti-EGFR-HGFR bispecific antibody
Condition: Thoracic

FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer

Trial: DeLLphi-304
Drug: Imdelltra (tarlatamab-dlle) · Anti-DLL3-CD3 bispecific antibody
Condition: Thoracic

FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer

Drug: Hyrnuo (sevabertinib) · ERBB2 inhibitor
Condition: Thoracic

FDA approves lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for extensive-stage small cell lung cancer

Trial: IMforte
Drugs: Zepzelca (lurbinectedin) · Alkylating agent, Tecentriq (atezolizumab) · Anti-PD-L1 antibody, Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) · Anti-PD-L1 antibody
Condition: Thoracic

FDA approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection

Trial: MK-3475A-D77
Drug: Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) · Anti-PD-1 antibody
Condition: Other solid neoplasm

FDA grants accelerated approval to zongertinib for non-squamous NSCLC with HER2 TKD activating mutations

Drug: Hernexeos (zongertinib) · ERBB2 inhibitor
Condition: Thoracic

FDA grants accelerated approval to sunvozertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations

Drug: Zegfrovy (sunvozertinib) · EGFR inhibitor
Condition: Thoracic

FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer

Drug: Datroway (datopotamab deruxtecan-dlnk) · Anti-TROP2 antibody-drug conjugate
Condition: Thoracic

FDA approves taletrectinib for ROS1-positive non-small cell lung cancer

Trial: TRUST-II
Drug: Ibtrozi (taletrectinib) · ROS1 inhibitor
Condition: Thoracic

FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression

Drug: Emrelis (telisotuzumab vedotin-tllv) · Anti-c-Met antibody-drug conjugate
Condition: Thoracic

FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection

Trial: CheckMate-67T
Drugs: Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) · Anti-PD-1 antibody, Opdivo (nivolumab) · Anti-PD-1 antibody
Conditions: DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer

Drug: Ensacove (ensartinib) · ALK inhibitor
Condition: Thoracic

FDA grants accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma

Drug: Bizengri (zenocutuzumab-zbco) · Anti-HER2-HER3 bispecific antibody
Conditions: GastrointestinalThoracic

FDA approves durvalumab for limited-stage small cell lung cancer

Trial: ADRIATIC
Drug: Imfinzi (durvalumab) · Anti-PD-L1 antibody
Condition: Thoracic

FDA approves neoadjuvant/adjuvant nivolumab for resectable non-small cell lung cancer

Drug: Opdivo (nivolumab) · Anti-PD-1 antibody
Condition: Thoracic

FDA approves osimertinib for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy

Trial: LAURA
Drug: Tagrisso (osimertinib) · EGFR inhibitor
Condition: Thoracic

FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations

Trial: MARIPOSA-2
Drugs: Rybrevant (amivantamab-vmjw) · Anti-EGFR-HGFR bispecific antibody, carboplatin · Platinum agent, pemetrexed · Antifolate
Condition: Thoracic

FDA approves pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma

Drugs: Keytruda (pembrolizumab) · Anti-PD-1 antibody, pemetrexed · Antifolate
Conditions: Other solid neoplasmThoracic

FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection

Drug: Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) · Anti-PD-L1 antibody
Conditions: DermatologicGastrointestinalSarcomaThoracic

FDA approves lazertinib with amivantamab-vmjw for non-small lung cancer

Trial: MARIPOSA
Drugs: Lazcluze (lazertinib) · EGFR inhibitor, Rybrevant (amivantamab-vmjw) · Anti-EGFR-HGFR bispecific antibody
Condition: Thoracic

FDA approves neoadjuvant/adjuvant durvalumab for resectable non-small cell lung cancer

Trial: AEGEAN
Drug: Imfinzi (durvalumab) · Anti-PD-L1 antibody
Condition: Thoracic

FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene fusion-positive solid tumors

Trial: TRIDENT-1
Drug: AUGTYRO (repotrectinib) · ROS1 inhibitor
Condition: Other solid neoplasm

FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer

Trial: DeLLphi-301
Drug: Imdelltra (tarlatamab-dlle) · Anti-DLL3-CD3 bispecific antibody
Condition: Thoracic

FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer

Drug: Alecensa (alectinib) · ALK inhibitor
Condition: Thoracic

FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors

Trials: DPT02, DESTINY-Lung01, DESTINY-CRC02
Drug: Enhertu (fam-trastuzumab deruxtecan-nxki) · Anti-HER2 antibody-drug conjugate
Condition: Other solid neoplasm

FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications

Trial: PAPILLON
Drugs: Rybrevant (amivantamab-vmjw) · Anti-EGFR-HGFR bispecific antibody, carboplatin · Platinum agent, pemetrexed · Antifolate
Condition: Thoracic

FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer

Trial: FLAURA2
Drug: Tagrisso (osimertinib) · EGFR inhibitor
Condition: Thoracic

FDA approves tepotinib for metastatic non-small cell lung cancer

Drug: Tepmetko (tepotinib) · MET inhibitor
Condition: Thoracic

FDA approves repotrectinib for ROS1-positive non-small cell lung cancer

Drug: Augtyro (repotrectinib) · ROS1 inhibitor
Condition: Thoracic

FDA expands pediatric indication for entrectinib and approves new pellet formulation

Trial: STARTRK-NG
Drug: Rozlytrek (entrectinib) · TRK inhibitor
Condition: Other solid neoplasm

FDA approves neoadjuvant/ adjuvant pembrolizumab for resectable non-small cell lung cancer

Trial: MK-3475-671
Drug: Keytruda (pembrolizumab) · Anti-PD-1 antibody
Condition: Thoracic

FDA approves encorafenib with binimetinib for metastatic non-small cell lung cancer with a BRAF V600E mutation

Drugs: Braftovi (encorafenib) · BRAF inhibitor, Mektovi (binimetinib) · MEK inhibitor
Condition: Thoracic

FDA approves pralsetinib for non-small cell lung cancer with RET gene fusions

Trial: ARROW
Drug: Gavreto (pralsetinib) · RET inhibitor
Condition: Thoracic

FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer

Trial: PEARLS
Drug: Keytruda (pembrolizumab) · Anti-PD-1 antibody
Condition: Thoracic

FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC

Drug: Krazati (adagrasib) · KRAS inhibitor
Condition: Thoracic

FDA approves tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small cell lung cancer

Trial: POSEIDON
Drugs: Imjudo (tremelimumab) · Anti-CTLA-4 antibody, Imfinzi (durvalumab) · Anti-PD-L1 antibody
Condition: Thoracic

FDA approves cemiplimab-rwlc in combination with platinum-based chemotherapy for non-small cell lung cancer

Drug: Libtayo (cemiplimab-rwlc) · Anti-PD-1 antibody
Condition: Thoracic

FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive non-small cell lung cancer

Drug: Retevmo (selpercatinib) · RET inhibitor
Condition: Thoracic

FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

Drug: Retevmo (selpercatinib) · RET inhibitor
Condition: Other solid neoplasm

FDA approves sodium thiosulfate to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors

Trial: SIOPEL6
Drug: Pedmark (sodium thiosulfate)
Condition: Other solid neoplasm

FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer

Trial: DESTINY-LUNG02
Drug: Enhertu (fam-trastuzumab deruxtecan-nxki) · Anti-HER2 antibody-drug conjugate
Condition: Thoracic

FDA approves capmatinib for metastatic non-small cell lung cancer

Drug: Tabrecta (capmatinib) · MET inhibitor
Condition: Thoracic

FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation

Drugs: Tafinlar (dabrafenib) · BRAF inhibitor, Mekinist (trametinib) · MEK inhibitor
Condition: Other solid neoplasm

FDA approves neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage non-small cell lung cancer

Trial: CheckMate 816
Drug: Opdivo (nivolumab) · Anti-PD-1 antibody
Condition: Thoracic

FDA approves atezolizumab as adjuvant treatment for non-small cell lung cancer

Drug: Tecentriq (atezolizumab) · Anti-PD-L1 antibody
Condition: Thoracic

FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations

Drug: Exkivity (mobocertinib) · EGFR inhibitor
Condition: Thoracic

FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors

Drug: Jemperli (dostarlimab-gxly) · Anti-PD-1 antibody
Condition: Other solid neoplasm

FDA grants accelerated approval to sotorasib for KRAS G12C mutated NSCLC

Drug: Lumakras (sotorasib) · KRAS inhibitor
Condition: Thoracic

FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer

Trial: CHRYSALIS
Drug: Rybrevant (amivantamab-vmjw) · Anti-EGFR-HGFR bispecific antibody
Condition: Thoracic

FDA approves lorlatinib for metastatic ALK-positive NSCLC

Drug: Lorbrena (lorlatinib) · ALK inhibitor
Condition: Thoracic

FDA approves cemiplimab-rwlc for non-small cell lung cancer with high PD-L1 expression

Drug: Libtayo (cemiplimab-rwlc) · Anti-PD-1 antibody
Condition: Thoracic

FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer

Drug: Tepmetko (tepotinib) · MET inhibitor
Condition: Thoracic

FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations

Trial: ADAURA
Drug: TAGRISSO (osimertinib) · EGFR inhibitor
Condition: Thoracic

FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations

Trial: ADAURA
Drug: TAGRISSO (osimertinib) · EGFR inhibitor
Condition: Thoracic

FDA approves liquid biopsy NGS companion diagnostic test for multiple cancers and biomarkers

Conditions: BreastGynecologicThoracic

FDA Approves Companion Diagnostic to identify NTRK fusions in solid tumors for Vitrakvi

Trials: SCOUT, NAVIGATE
Condition: Other solid neoplasm

FDA Approves Companion Diagnostic to identify NTRK fusions in solid tumors for Vitrakvi

Trials: SCOUT, NAVIGATE
Condition: Other solid neoplasm

FDA approves nivolumab and ipilimumab for unresectable malignant pleural mesothelioma

Trial: CheckMate743
Drugs: OPDIVO (nivolumab) · Anti-PD-1 antibody, YERVOY (ipilimumab) · Anti-CTLA-4 antibody
Conditions: Other solid neoplasmThoracic

FDA approves nivolumab and ipilimumab for unresectable malignant pleural mesothelioma

Trial: CheckMate743
Drugs: OPDIVO (nivolumab) · Anti-PD-1 antibody, YERVOY (ipilimumab) · Anti-CTLA-4 antibody
Conditions: Other solid neoplasmThoracic

FDA approves pralsetinib for lung cancer with RET gene fusions

Drug: GAVRETO (pralsetinib) · RET inhibitor
Condition: Thoracic

FDA approves pralsetinib for lung cancer with RET gene fusions

Drug: GAVRETO (pralsetinib) · RET inhibitor
Condition: Thoracic

FDA approves pembrolizumab for adults and children with TMB-H solid tumors

Trial: KEYNOTE 158
Drug: KEYTRUDA (pembrolizumab) · Anti-PD-1 antibody
Condition: Other solid neoplasm

FDA approves pembrolizumab for adults and children with TMB-H solid tumors

Drug: KEYTRUDA (pembrolizumab) · Anti-PD-1 antibody
Condition: Other solid neoplasm

FDA grants accelerated approval to lurbinectedin for metastatic small cell lung cancer

Drug: ZEPZELCA (lurbinectedin) · Alkylating agent
Condition: Thoracic

FDA grants accelerated approval to lurbinectedin for metastatic small cell lung cancer

Drug: ZEPZELCA (lurbinectedin) · Alkylating agent
Condition: Thoracic

FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC

Trial: RELAY
Drugs: CYRAMZA (ramucirumab) · Anti-VEGFR antibody, erlotinib · EGFR inhibitor
Condition: Thoracic

FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC

Trial: RELAY
Drugs: CYRAMZA (ramucirumab) · Anti-VEGFR antibody, erlotinib · EGFR inhibitor
Condition: Thoracic

FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC

Trial: CheckMate 9LA
Drugs: OPDIVO (nivolumab) · Anti-PD-1 antibody, YERVOY (ipilimumab) · Anti-CTLA-4 antibody
Condition: Thoracic

FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC

Trial: CheckMate 9LA
Drugs: OPDIVO (nivolumab) · Anti-PD-1 antibody, YERVOY (ipilimumab) · Anti-CTLA-4 antibody
Condition: Thoracic

FDA approves brigatinib for ALK-positive metastatic NSCLC

Trial: ALTA-1L
Drug: ALUNBRIG (brigatinib) · ALK inhibitor
Condition: Thoracic

FDA approves brigatinib for ALK-positive metastatic NSCLC

Trial: ALTA-1L
Drug: ALUNBRIG (brigatinib) · ALK inhibitor
Condition: Thoracic

FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression

Drug: TECENTRIQ (atezolizumab) · Anti-PD-L1 antibody
Condition: Thoracic

FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression

Drug: TECENTRIQ (atezolizumab) · Anti-PD-L1 antibody
Condition: Thoracic

FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%)

Trial: CheckMate 227
Drugs: OPDIVO (nivolumab) · Anti-PD-1 antibody, YERVOY (ipilimumab) · Anti-CTLA-4 antibody
Condition: Thoracic

FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%)

Trial: CheckMate 227
Drugs: OPDIVO (nivolumab) · Anti-PD-1 antibody, YERVOY (ipilimumab) · Anti-CTLA-4 antibody
Condition: Thoracic

FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer

Drug: TABRECTA (capmatinib) · MET inhibitor
Condition: Thoracic

FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer

Drug: TABRECTA (capmatinib) · MET inhibitor
Condition: Thoracic

FDA approves durvalumab for extensive-stage small cell lung cancer

Trial: CASPIAN
Drugs: IMFINZI (durvalumab) · Anti-PD-L1 antibody, etoposide · Topoisomerase II inhibitor
Condition: Thoracic

FDA approves durvalumab for extensive-stage small cell lung cancer

Trial: CASPIAN
Drugs: IMFINZI (durvalumab) · Anti-PD-L1 antibody, etoposide · Topoisomerase II inhibitor
Condition: Thoracic

FDA approves atezolizumab with nab-paclitaxel and carboplatin for metastatic NSCLC without EGFR/ALK aberrations

Trial: IMpower130
Drugs: TECENTRIQ (atezolizumab) · Anti-PD-L1 antibody, paclitaxel protein-bound · Taxane, carboplatin · Platinum agent
Condition: Thoracic

FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC

Trials: STARTRK-1, STARTRK-2
Drug: ROZLYTREK (entrectinib) · TRK inhibitor
Conditions: Other solid neoplasmThoracic

FDA approves pembrolizumab for metastatic small cell lung cancer

Trial: MK-3475-028
Drug: KEYTRUDA (pembrolizumab) · Anti-PD-1 antibody
Condition: Thoracic

FDA expands pembrolizumab indication for first-line treatment of NSCLC (TPS ≥1%)

Trial: Keynote 042
Drug: KEYTRUDA (pembrolizumab) · Anti-PD-1 antibody
Condition: Thoracic

FDA approves atezolizumab for extensive-stage small cell lung cancer

Trial: IMpower133
Drugs: TECENTRIQ (atezolizumab) · Anti-PD-L1 antibody, carboplatin · Platinum agent, etoposide · Topoisomerase II inhibitor
Condition: Thoracic

Atezolizumab (TECENTRIQ)

Drug: TECENTRIQ (atezolizumab) · Anti-PD-L1 antibody
Conditions: GenitourinaryThoracic

FDA approves larotrectinib for solid tumors with NTRK gene fusions

Drug: VITRAKVI (larotrectinib) · TRK inhibitor
Condition: Other solid neoplasm

FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

Drug: LORBRENA (lorlatinib) · ALK inhibitor
Condition: Thoracic

FDA approves pembrolizumab in combination with chemotherapy for first-line treatment of metastatic squamous NSCLC

Trial: KEYNOTE-407
Drugs: KEYTRUDA (pembrolizumab) · Anti-PD-1 antibody, carboplatin · Platinum agent
Condition: Thoracic

FDA approves dacomitinib for metastatic non-small cell lung cancer

Drug: VIZIMPRO (dacomitinib) · EGFR inhibitor
Condition: Thoracic

FDA grants regular approval for pembrolizumab in combination with chemotherapy for first-line treatment of metastatic nonsquamous NSCLC

Trial: MK-3475-189
Drugs: KEYTRUDA (pembrolizumab) · Anti-PD-1 antibody, pemetrexed · Antifolate
Condition: Thoracic

FDA grants nivolumab accelerated approval for third-line treatment of metastatic small cell lung cancer

Drug: Opdivo (nivolumab) · Anti-PD-1 antibody
Condition: Thoracic

FDA approves osimertinib for first-line treatment of metastatic NSCLC with most common EGFR mutations

Trial: FLAURA
Drug: Tagrisso (osimertinib) · EGFR inhibitor
Condition: Thoracic

FDA approves durvalumab after chemoradiation for unresectable stage III NSCLC

Trial: PACIFIC
Drug: Imfinzi (durvalumab) · Anti-PD-L1 antibody
Condition: Thoracic

FDA broadens afatinib indication to previously untreated, metastatic NSCLC with other non-resistant EGFR mutations

Drug: Gilotrif (afatinib) · EGFR inhibitor
Condition: Thoracic

FDA grants marketing approval to FoundationOne CDx in vitro diagnostic

Conditions: BreastDermatologicGastrointestinalGynecologicThoracic

Alectinib approved for (ALK) positive metastatic non-small cell lung cancer (NSCLC)

Trial: ALEX
Drug: ALECENSA (alectinib) · ALK inhibitor
Condition: Thoracic

FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation

Drugs: TAFINLAR (dabrafenib) · BRAF inhibitor, MEKINIST (trametinib) · MEK inhibitor
Condition: Thoracic

FDA broadens ceritinib indication to previously untreated ALK-positive metastatic NSCLC

Drug: ZYKADIA (ceritinib) · ALK inhibitor
Condition: Thoracic

Pembrolizumab (Keytruda) 5-10-2017

Drugs: KEYTRUDA (pembrolizumab) · Anti-PD-1 antibody, pemetrexed · Antifolate, carboplatin · Platinum agent
Condition: Thoracic

Pembrolizumab (KEYTRUDA) Checkpoint Inhibitor

Drug: KEYTRUDA (pembrolizumab) · Anti-PD-1 antibody
Condition: Thoracic

Erlotinib (Tarceva)

Drug: TARCEVA (erlotinib) · EGFR inhibitor
Condition: Thoracic

Atezolizumab (TECENTRIQ)

Drug: TECENTRIQ (atezolizumab) · Anti-PD-L1 antibody
Conditions: GenitourinaryThoracic

Modification of the Dosage Regimen for Nivolumab

Conditions: DermatologicGenitourinaryThoracic

cobas EGFR Mutation Test v2

Drug: Roche Molecular Systems (cobas EGFR Mutation Test v2)
Condition: Thoracic

FDA Approves Crizotinib Capsules

Drug: Xalkori (crizotinib) · ALK inhibitor
Condition: Thoracic

Alectinib

Drug: ALECENSA capsules (alectinib) · ALK inhibitor
Condition: Thoracic

Necitumumab

Drugs: PORTRAZZA (necitumumab) · Anti-EGFR antibody, gemcitabine · Pyrimidine analog, cisplatin · Platinum agent
Condition: Thoracic

Osimertinib

Drug: TAGRISSO (osimertinib) · EGFR inhibitor
Condition: Thoracic

Nivolumab Injection

Drug: Opdivo (nivolumab) · Anti-PD-1 antibody
Condition: Thoracic

Pembrolizumab injection

Drug: KEYTRUDA (pembrolizumab) · Anti-PD-1 antibody
Condition: Thoracic

Gefitinib (Iressa)

Drug: IRESSA (gefitinib) · EGFR inhibitor
Condition: Thoracic

Nivolumab (Opdivo)

Drug: OPDIVO (nivolumab) · Anti-PD-1 antibody
Conditions: DermatologicThoracic

Ramucirumab (Cyramza)

Drugs: Cyramza (ramucirumab) · Anti-VEGFR antibody, docetaxel · Taxane, paclitaxel · Taxane
Condition: Thoracic

FDA Approves Ceritinib

Drug: ZYKADIA (ceritinib) · ALK inhibitor
Condition: Thoracic

FDA Approves Crizotinib

Drug: Xalkori (crizotinib) · ALK inhibitor
Condition: Thoracic

FDA Approves Afatinib

Drug: Gilotrif tablets (afatinib) · EGFR inhibitor
Condition: Thoracic

FDA Approves Erlotinib

Drug: Tarceva (erlotinib) · EGFR inhibitor
Condition: Thoracic

Pemetrexed

Drug: ALIMTA (pemetrexed) · Antifolate
Condition: Thoracic

Paclitaxel (Abraxane)

Drugs: ABRAXANE (albumin-bound) , carboplatin · Platinum agent
Condition: Thoracic

Crizotinib

Drug: XALKORI Capsules (crizotinib) · ALK inhibitor
Condition: Thoracic

Erlotinib

Drug: Tarceva (erlotinib) · EGFR inhibitor
Condition: Thoracic

Pemetrexed Injection

Drug: Alimta (pemetrexed) · Antifolate
Condition: Thoracic

Alimta Injection

Drug: Alimta (pemetrexed) · Antifolate
Condition: Thoracic

FDA approves bevacizumab (Avastin) as a first-line treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer in combination with platinum-based chemotherapy

Condition: Thoracic